Biocon Q1 FY27 Results (NSE: BIOCON)
Signal: Growth reaccelerated
The read
The business mix is improving as Biopharma revenue grew 17% YoY and offset a 16% Services decline, but the trajectory is not yet a clean earnings compounding story: EBITDA margin was 20.8%, broadly flat YoY and down from roughly 24% in Q4FY26, while PAT growth to ₹141.1 crore was amplified by minority interest falling to ₹1 crore from ₹61 crore and by non-operating items.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹4,336 Cr | +10% | -4% |
| EBIT | ₹354.3 Cr | N/A | |
| Net profit | ₹141.1 Cr | +355% | |
| EPS | ₹0.87 | +278.3% | |
| EBIT margin | 20.8% |
P&L walk
Revenue increased 10% YoY to ₹4,336 crore on 17% Biopharma growth, while EBITDA rose 7% to ₹901.7 crore and margin was broadly flat at 20.8%; lower interest cost helped, but depreciation rose 20% and reported PAT was materially aided by lower minority interest and non-operating items.
Segments
Biopharma was the clear growth engine at ₹3,615 crore of revenue, up 17% YoY, led by Biosimilars at ₹2,855 crore, up 16%, and Generics at ₹760 crore, up 21%; Services dragged with revenue down 16% to ₹736 crore.
Key positives
- Biopharma revenue increased 17% YoY to ₹3,615 crore, with Generics up 21% to ₹760 crore and Biosimilars up 16% to ₹2,855 crore.
- Interest cost declined 23% YoY to ₹213 crore following balance-sheet optimisation, supporting PBT before exceptional items growth of 24% to ₹141 crore.
- New U.S. launches including Bosaya, Aukelso, Yesafili and generic Liraglutide expand the commercial biosimilar and complex-generics platform.
Key concerns
- Services revenue declined 16% YoY to ₹736 crore, and management described Syngene as navigating current headwinds.
- EBITDA grew only 7% YoY to ₹901.7 crore despite 10% revenue growth, leaving EBITDA margin broadly flat at 20.8% and below the prior quarter.
- R&D expenses rose 17% YoY to ₹240 crore, increasing investment intensity while Services revenue remained under pressure.
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.